Last reviewed · How we verify
GSK3511294 (Depemokimab)
Depemokimab is a monoclonal antibody that inhibits interleukin-4 receptor alpha (IL-4Rα) to reduce type 2 inflammatory responses.
Depemokimab is a monoclonal antibody that inhibits interleukin-4 receptor alpha (IL-4Rα) to reduce type 2 inflammatory responses. Used for Moderate-to-severe atopic dermatitis, Eosinophilic esophagitis.
At a glance
| Generic name | GSK3511294 (Depemokimab) |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | IL-4 receptor alpha antagonist |
| Target | IL-4Rα (Interleukin-4 receptor alpha) |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
IL-4Rα is a key component of both IL-4 and IL-13 signaling pathways, which drive type 2 inflammation. By blocking this receptor, depemokimab reduces the production of IgE and other markers of allergic and eosinophilic inflammation. This mechanism is intended to treat conditions characterized by excessive type 2 immune responses.
Approved indications
- Moderate-to-severe atopic dermatitis
- Eosinophilic esophagitis
Common side effects
- Injection site reactions
- Headache
- Upper respiratory tract infection
Key clinical trials
- A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma (PHASE3)
- An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103) (PHASE3)
- Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps (PHASE3)
- A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype (PHASE3)
- Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1) (PHASE3)
- Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps (ANCHOR-2) (PHASE3)
- Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2) (PHASE3)
- Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK3511294 (Depemokimab) CI brief — competitive landscape report
- GSK3511294 (Depemokimab) updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI